BioCentury | May 31, 2010
Finance

Performance Counts

...It lashed on the drug discovery service operations of Discovery Partners International Inc. and the Proskelia...
...the clinic, a selective androgen receptor modulator (SARM) to treat cachexia, was obtained through the ProSkelia...
...in 2010 NA Platform: drug delivery Duodopa levodopa/carbidopa [Uppsala University] 2009 Duodopa sales: €59M ($84.9M) ProSkelia...
BioCentury | Jul 30, 2007
Company News

Galapagos, Boehringer Ingelheim, ProStrakan, Novartis deal

...a $1 million milestone payment from NVS under a September deal between the pharma and ProSkelia...
BioCentury | Jan 8, 2007
Finance

Europe's As & Bs

...Europe's As & Bs Company Date Round Raised Biovitrum 8/1/01 Series A €96.7 Proskelia (A) 7/9/02...
BioCentury | Jan 1, 2007
Strategy

Double-dipping on ProSkelia

...Mechelen, Belgium) took a major step toward clinical development. The company said it would acquire ProSkelia...
...2006 with about E51 million ($66.8 million) in cash (see B30). GLPG will get four ProSkelia...
...optimization, and the company hopes to announce a preclinical RA candidate in 2007. Under the ProSkelia...
BioCentury | Jan 1, 2007
Company News

Galapagos, ProStrakan deal

...GLPG agreed to acquire PSK's ProSkelia French drug discovery subsidiary for E12.5 million ($16.4 million) in...
...PSK is eligible for E14.5 million ($19.1 million) in additional payments. GLPG also would assume ProSkelia's...
...has the right of first refusal on the cachexia program and also retains two other ProSkelia...
BioCentury | Dec 27, 2006
Financial News

Galapagos raises EUR 31M, to acquire ProSkelia

...Fortis; and Whitaker Securities were joint lead managers. GLPG also said it agreed to acquire ProSkelia...
...is eligible for EUR 14.5 million ($19.1 million) in additional payments. GLPG also would assume ProSkelia's...
...has the right of first refusal on the cachexia program and also retains two other ProSkelia...
BioCentury | Oct 2, 2006
Company News

ProStrakan, Novartis deal

...and commercialization. PSK retains rights to small molecules against the target. The target came from ProSkelia...
BioCentury | Oct 31, 2005
Finance

Liquidity preference

...it was coming from. The company was created by the merger of French musculoskeletal play Proskelia...
BioCentury | May 9, 2005
Strategy

Acquiring markets

...When French drug discovery play ProSkelia SA and U.K. specialty pharma Strakan Group Ltd. merged last...
BioCentury | Apr 18, 2005
Finance

Ebb & Flow

...public mid-year (see BioCentury, Dec. 6, 2004). The company, formed by the merger of France's ProSkelia...
Items per page:
1 - 10 of 52
BioCentury | May 31, 2010
Finance

Performance Counts

...It lashed on the drug discovery service operations of Discovery Partners International Inc. and the Proskelia...
...the clinic, a selective androgen receptor modulator (SARM) to treat cachexia, was obtained through the ProSkelia...
...in 2010 NA Platform: drug delivery Duodopa levodopa/carbidopa [Uppsala University] 2009 Duodopa sales: €59M ($84.9M) ProSkelia...
BioCentury | Jul 30, 2007
Company News

Galapagos, Boehringer Ingelheim, ProStrakan, Novartis deal

...a $1 million milestone payment from NVS under a September deal between the pharma and ProSkelia...
BioCentury | Jan 8, 2007
Finance

Europe's As & Bs

...Europe's As & Bs Company Date Round Raised Biovitrum 8/1/01 Series A €96.7 Proskelia (A) 7/9/02...
BioCentury | Jan 1, 2007
Strategy

Double-dipping on ProSkelia

...Mechelen, Belgium) took a major step toward clinical development. The company said it would acquire ProSkelia...
...2006 with about E51 million ($66.8 million) in cash (see B30). GLPG will get four ProSkelia...
...optimization, and the company hopes to announce a preclinical RA candidate in 2007. Under the ProSkelia...
BioCentury | Jan 1, 2007
Company News

Galapagos, ProStrakan deal

...GLPG agreed to acquire PSK's ProSkelia French drug discovery subsidiary for E12.5 million ($16.4 million) in...
...PSK is eligible for E14.5 million ($19.1 million) in additional payments. GLPG also would assume ProSkelia's...
...has the right of first refusal on the cachexia program and also retains two other ProSkelia...
BioCentury | Dec 27, 2006
Financial News

Galapagos raises EUR 31M, to acquire ProSkelia

...Fortis; and Whitaker Securities were joint lead managers. GLPG also said it agreed to acquire ProSkelia...
...is eligible for EUR 14.5 million ($19.1 million) in additional payments. GLPG also would assume ProSkelia's...
...has the right of first refusal on the cachexia program and also retains two other ProSkelia...
BioCentury | Oct 2, 2006
Company News

ProStrakan, Novartis deal

...and commercialization. PSK retains rights to small molecules against the target. The target came from ProSkelia...
BioCentury | Oct 31, 2005
Finance

Liquidity preference

...it was coming from. The company was created by the merger of French musculoskeletal play Proskelia...
BioCentury | May 9, 2005
Strategy

Acquiring markets

...When French drug discovery play ProSkelia SA and U.K. specialty pharma Strakan Group Ltd. merged last...
BioCentury | Apr 18, 2005
Finance

Ebb & Flow

...public mid-year (see BioCentury, Dec. 6, 2004). The company, formed by the merger of France's ProSkelia...
Items per page:
1 - 10 of 52